Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

The Aged Microenvironment Influences the Tumorigenic Potential of Malignant Prostate Epithelial Cells.

Bianchi-Frias D, Damodarasamy M, Hernandez SA, Gil da Costa RM, Vakar-Lopez F, Coleman IM, Reed MJ, Nelson PS.

Mol Cancer Res. 2019 Jan;17(1):321-331. doi: 10.1158/1541-7786.MCR-18-0522. Epub 2018 Sep 17.

PMID:
30224545
2.

Divergent Biological Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer.

Seiler R, Gibb EA, Wang NQ, Oo HZ, Lam HM, van Kessel KE, Voskuilen CS, Winters B, Erho N, Takhar MM, Douglas J, Vakar-Lopez F, Crabb SJ, van Rhijn BWG, Fransen van de Putte EE, Zwarthoff EC, Thalmann GN, Davicioni E, Boormans JL, Dall'Era M, van der Heijden MS, Wright JL, Black PC.

Clin Cancer Res. 2018 Sep 17. doi: 10.1158/1078-0432.CCR-18-1106. [Epub ahead of print]

PMID:
30224344
3.

Mechanistic target of rapamycin (MTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomy.

Winters BR, Vakar-Lopez F, Brown L, Montgomery B, Seiler R, Black PC, Boormans JL, Dall Era M, Davincioni E, Douglas J, Gibb EA, van Rhijn BWG, van der Heijden MS, Hsieh AC, Wright JL, Lam HM.

Urol Oncol. 2018 Jul;36(7):342.e7-342.e14. doi: 10.1016/j.urolonc.2018.03.016. Epub 2018 Apr 12.

4.

Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate.

Schweizer MT, Cheng HH, Tretiakova MS, Vakar-Lopez F, Klemfuss N, Konnick EQ, Mostaghel EA, Nelson PS, Yu EY, Montgomery B, True LD, Pritchard CC.

Oncotarget. 2016 Dec 13;7(50):82504-82510. doi: 10.18632/oncotarget.12697.

5.

Histologic Grading of Prostatic Adenocarcinoma Can Be Further Optimized: Analysis of the Relative Prognostic Strength of Individual Architectural Patterns in 1275 Patients From the Canary Retrospective Cohort.

McKenney JK, Wei W, Hawley S, Auman H, Newcomb LF, Boyer HD, Fazli L, Simko J, Hurtado-Coll A, Troyer DA, Tretiakova MS, Vakar-Lopez F, Carroll PR, Cooperberg MR, Gleave ME, Lance RS, Lin DW, Nelson PS, Thompson IM, True LD, Feng Z, Brooks JD.

Am J Surg Pathol. 2016 Nov;40(11):1439-1456.

PMID:
27635949
6.

Flat Urothelial Lesions With Atypia: Interobserver Concordance and Added Value of Immunohistochemical Profiling.

Lawless ME, Tretiakova MS, True LD, Vakar-Lopez F.

Appl Immunohistochem Mol Morphol. 2018 Mar;26(3):180-185. doi: 10.1097/PAI.0000000000000401.

PMID:
27299187
7.

A Novel System for Estimating Residual Disease and Pathologic Response to Neoadjuvant Treatment of Prostate Cancer.

Murphy C, True L, Vakar-Lopez F, Xia J, Gulati R, Montgomery B, Tretiakova M.

Prostate. 2016 Oct;76(14):1285-92. doi: 10.1002/pros.23215. Epub 2016 Jun 8.

8.

Prognostic value of Ki67 in localized prostate carcinoma: a multi-institutional study of >1000 prostatectomies.

Tretiakova MS, Wei W, Boyer HD, Newcomb LF, Hawley S, Auman H, Vakar-Lopez F, McKenney JK, Fazli L, Simko J, Troyer DA, Hurtado-Coll A, Thompson IM Jr, Carroll PR, Ellis WJ, Gleave ME, Nelson PS, Lin DW, True LD, Feng Z, Brooks JD.

Prostate Cancer Prostatic Dis. 2016 Sep;19(3):264-70. doi: 10.1038/pcan.2016.12. Epub 2016 May 3.

9.

Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort.

Newcomb LF, Thompson IM Jr, Boyer HD, Brooks JD, Carroll PR, Cooperberg MR, Dash A, Ellis WJ, Fazli L, Feng Z, Gleave ME, Kunju P, Lance RS, McKenney JK, Meng MV, Nicolas MM, Sanda MG, Simko J, So A, Tretiakova MS, Troyer DA, True LD, Vakar-Lopez F, Virgin J, Wagner AA, Wei JT, Zheng Y, Nelson PS, Lin DW; Canary PASS Investigators.

J Urol. 2016 Feb;195(2):313-20. doi: 10.1016/j.juro.2015.08.087. Epub 2015 Aug 29.

10.

Surgical pathology and the patient: a systematic review evaluating the primary audience of pathology reports.

Mossanen M, True LD, Wright JL, Vakar-Lopez F, Lavallee D, Gore JL.

Hum Pathol. 2014 Nov;45(11):2192-201. doi: 10.1016/j.humpath.2014.07.008. Epub 2014 Jul 25. Review.

PMID:
25149550
11.

A novel four-color fluorescence in situ hybridization assay for the detection of TMPRSS2 and ERG rearrangements in prostate cancer.

Qu X, Randhawa G, Friedman C, O'Hara-Larrivee S, Kroeger K, Dumpit R, True L, Vakar-Lopez F, Porter C, Vessella R, Nelson P, Fang M.

Cancer Genet. 2013 Jan-Feb;206(1-2):1-11. doi: 10.1016/j.cancergen.2012.12.004. Epub 2013 Jan 24.

12.

Radiologic-pathologic findings of solitary fibrous tumor of the prostate presenting as a large mass with delayed filling-in on MRI.

Bhargava P, Lee JH, Gupta S, Seyal AR, Vakar-Lopez F, Moshiri M, Dighe MK.

Radiol Case Rep. 2015 Dec 7;7(1):634. doi: 10.2484/rcr.v7i1.634. eCollection 2012.

13.

Androgen receptor variants occur frequently in castration resistant prostate cancer metastases.

Zhang X, Morrissey C, Sun S, Ketchandji M, Nelson PS, True LD, Vakar-Lopez F, Vessella RL, Plymate SR.

PLoS One. 2011;6(11):e27970. doi: 10.1371/journal.pone.0027970. Epub 2011 Nov 17.

14.

Testosterone regulates tight junction proteins and influences prostatic autoimmune responses.

Meng J, Mostaghel EA, Vakar-Lopez F, Montgomery B, True L, Nelson PS.

Horm Cancer. 2011 Jun;2(3):145-56. doi: 10.1007/s12672-010-0063-1.

15.

The potential impact of reproducibility of Gleason grading in men with early stage prostate cancer managed by active surveillance: a multi-institutional study.

McKenney JK, Simko J, Bonham M, True LD, Troyer D, Hawley S, Newcomb LF, Fazli L, Kunju LP, Nicolas MM, Vakar-Lopez F, Zhang X, Carroll PR, Brooks JD; Canary/Early Detection Research Network Prostate Active Surveillance Study Investigators.

J Urol. 2011 Aug;186(2):465-9. doi: 10.1016/j.juro.2011.03.115. Epub 2011 Jun 15.

PMID:
21679996
16.

Ductal adenocarcinoma of the prostate: increased mortality risk and decreased serum prostate specific antigen.

Morgan TM, Welty CJ, Vakar-Lopez F, Lin DW, Wright JL.

J Urol. 2010 Dec;184(6):2303-7. doi: 10.1016/j.juro.2010.08.017. Epub 2010 Oct 16.

17.

The effects of aging on the molecular and cellular composition of the prostate microenvironment.

Bianchi-Frias D, Vakar-Lopez F, Coleman IM, Plymate SR, Reed MJ, Nelson PS.

PLoS One. 2010 Sep 1;5(9). pii: e12501. doi: 10.1371/journal.pone.0012501.

18.

Effect of artemisinin derivatives on apoptosis and cell cycle in prostate cancer cells.

Morrissey C, Gallis B, Solazzi JW, Kim BJ, Gulati R, Vakar-Lopez F, Goodlett DR, Vessella RL, Sasaki T.

Anticancer Drugs. 2010 Apr;21(4):423-32. doi: 10.1097/CAD.0b013e328336f57b.

19.

The expression of osteoclastogenesis-associated factors and osteoblast response to osteolytic prostate cancer cells.

Morrissey C, Lai JS, Brown LG, Wang YC, Roudier MP, Coleman IM, Gulati R, Vakar-Lopez F, True LD, Corey E, Nelson PS, Vessella RL.

Prostate. 2010 Mar 1;70(4):412-24. doi: 10.1002/pros.21075.

20.

Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer.

Tsavachidou D, McDonnell TJ, Wen S, Wang X, Vakar-Lopez F, Pisters LL, Pettaway CA, Wood CG, Do KA, Thall PF, Stephens C, Efstathiou E, Taylor R, Menter DG, Troncoso P, Lippman SM, Logothetis CJ, Kim J.

J Natl Cancer Inst. 2009 Mar 4;101(5):306-20. doi: 10.1093/jnci/djn512. Epub 2009 Feb 24.

21.

Muscularis mucosae of the urinary bladder revisited with emphasis on its hyperplastic patterns: a study of a large series of cystectomy specimens.

Vakar-Lopez F, Shen SS, Zhang S, Tamboli P, Ayala AG, Ro JY.

Ann Diagn Pathol. 2007 Dec;11(6):395-401. Epub 2007 Oct 24.

PMID:
18022122
22.

How wide is the spectrum of neuroendocrine carcinoma of the urinary bladder?

Vakar-Lopez F, True LD.

Am J Clin Pathol. 2007 Nov;128(5):723-5. No abstract available.

PMID:
17951191
23.

Treatment outcomes of small cell carcinoma of the prostate: a single-center study.

Spiess PE, Pettaway CA, Vakar-Lopez F, Kassouf W, Wang X, Busby JE, Do KA, Davuluri R, Tannir NM.

Cancer. 2007 Oct 15;110(8):1729-37.

24.

Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone.

Li ZG, Yang J, Vazquez ES, Rose D, Vakar-Lopez F, Mathew P, Lopez A, Logothetis CJ, Lin SH, Navone NM.

Oncogene. 2008 Jan 24;27(5):596-603. Epub 2007 Aug 13.

PMID:
17700537
25.

Bone microenvironment and androgen status modulate subcellular localization of ErbB3 in prostate cancer cells.

Cheng CJ, Ye XC, Vakar-Lopez F, Kim J, Tu SM, Chen DT, Navone NM, Yu-Lee LY, Lin SH, Hu MC.

Mol Cancer Res. 2007 Jul;5(7):675-84.

26.

Primary angiosarcoma of the bladder.

Seethala RR, Gomez JA, Vakar-Lopez F.

Arch Pathol Lab Med. 2006 Oct;130(10):1543-7.

PMID:
17090199
27.

Histological changes in prostate biopsies after salvage cryotherapy: effect of chronology and the method of biopsy.

Izawa JI, Busby JE, Morganstern N, Vakar-Lopez F, Scott SM, Pisters LL.

BJU Int. 2006 Sep;98(3):554-8.

28.

Protracted remission of metastatic epithelioid angiosarcoma with weekly infusion of doxorubicin, paclitaxel, and cisplatin.

Mathew P, Vakar-Lopez F, Troncoso P.

Lancet Oncol. 2006 Jan;7(1):92-3. No abstract available.

PMID:
16389189
29.

Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy.

Tu SM, Kim J, Pagliaro LC, Vakar-Lopez F, Wong FC, Wen S, General R, Podoloff DA, Lin SH, Logothetis CJ.

J Clin Oncol. 2005 Nov 1;23(31):7904-10.

PMID:
16258090
30.

Port-site metastasis: the influence of biology.

Highshaw RA, Vakar-Lopez F, Jonasch E, Yasko AW, Matin SF.

Eur Urol. 2005 Mar;47(3):357-60. Epub 2005 Jan 15.

PMID:
15716201
31.

Up-regulation of MDA-BF-1, a secreted isoform of ErbB3, in metastatic prostate cancer cells and activated osteoblasts in bone marrow.

Vakar-Lopez F, Cheng CJ, Kim J, Shi GG, Troncoso P, Tu SM, Yu-Lee LY, Lin SH.

J Pathol. 2004 Jun;203(2):688-95.

PMID:
15141384
32.

Identification of Sp2 as a transcriptional repressor of carcinoembryonic antigen-related cell adhesion molecule 1 in tumorigenesis.

Phan D, Cheng CJ, Galfione M, Vakar-Lopez F, Tunstead J, Thompson NE, Burgess RR, Najjar SM, Yu-Lee LY, Lin SH.

Cancer Res. 2004 May 1;64(9):3072-8.

33.

Glycogen synthase kinase-3 beta is involved in the phosphorylation and suppression of androgen receptor activity.

Salas TR, Kim J, Vakar-Lopez F, Sabichi AL, Troncoso P, Jenster G, Kikuchi A, Chen SY, Shemshedini L, Suraokar M, Logothetis CJ, DiGiovanni J, Lippman SM, Menter DG.

J Biol Chem. 2004 Apr 30;279(18):19191-200. Epub 2004 Feb 24.

34.

Bcl-2 is significantly overexpressed in localized radio-recurrent prostate carcinoma, compared with localized radio-naive prostate carcinoma.

Rosser CJ, Reyes AO, Vakar-Lopez F, Levy LB, Kuban DA, Hoover DC, Lee AK, Pisters LL.

Int J Radiat Oncol Biol Phys. 2003 May 1;56(1):1-6.

PMID:
12694817
35.

Predictors of cancer in repeat extended multisite prostate biopsy in men with previous negative extended multisite biopsy.

Mian BM, Naya Y, Okihara K, Vakar-Lopez F, Troncoso P, Babaian RJ.

Urology. 2002 Nov;60(5):836-40.

PMID:
12429311
36.

Amplification/overexpression of a mitotic kinase gene in human bladder cancer.

Sen S, Zhou H, Zhang RD, Yoon DS, Vakar-Lopez F, Ito S, Jiang F, Johnston D, Grossman HB, Ruifrok AC, Katz RL, Brinkley W, Czerniak B.

J Natl Cancer Inst. 2002 Sep 4;94(17):1320-9.

PMID:
12208897
37.

Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features.

Maruyama R, Toyooka S, Toyooka KO, Harada K, Virmani AK, Zöchbauer-Müller S, Farinas AJ, Vakar-Lopez F, Minna JD, Sagalowsky A, Czerniak B, Gazdar AF.

Cancer Res. 2001 Dec 15;61(24):8659-63.

38.

Epithelial Phenotype in Ewing's Sarcoma/Primitive Neuroectodermal Tumor.

Vakar-López F, Ayala AG, Raymond AK, Czerniak B.

Int J Surg Pathol. 2000 Jan;8(1):59-65.

PMID:
11493965
39.

Basaloid squamous cell carcinoma occurring in the urinary bladder.

Vakar-López F, Abrams J.

Arch Pathol Lab Med. 2000 Mar;124(3):455-9.

PMID:
10705407
40.

Peripheral T-cell lymphoma presenting as ascites: a case report and review of the literature.

Vakar-López F, Yang M.

Diagn Cytopathol. 1999 Jun;20(6):382-4. Review.

PMID:
10352913

Supplemental Content

Loading ...
Support Center